Data from A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
X. Cynthia, Matthew J. Ellis(University of California, Davis), Obi L. Griffith(Washington University in St. Louis), Rama Suresh(Washington University in St. Louis), Jeremy Hoog(Washington University in St. Louis), Shana Thomas, Malachi Griffith(Washington University in St. Louis), Jingqin Luo(Washington University in St. Louis), Timothy Pluard(Southwestern Medical Center), Zachary L. Skidmore(James S. McDonnell Foundation), Avinash Ramu(James S. McDonnell Foundation), Elaine R. Mardis(Nationwide Children's Hospital), Nicholas C. Spies(James S. McDonnell Foundation), Foluso O. Ademuyiwa(Washington University in St. Louis), Lee Trani(James S. McDonnell Foundation), Michael Naughton(Boston College), Zhanfang Guo(Washington University in St. Louis), Gayathri Nagaraj(Loma Linda University), Jing Han(Hebei Medical University), Craig Lockhart
Cited by 0
Related Papers
A global reference for human genetic variation
|Nature|2015|20.3k
Finding the missing heritability of complex diseases
|Nature|2009|8.5k
Somatic mutations affect key pathways in lung adenocarcinoma
|Nature|2008|2.8k
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
|Nature|2012|2k
Evolutionary and Biomedical Insights from the Rhesus Macaque Genome
|Science|2007|1.5k